Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Survival Impact of Fluoropyrimidine Metronomic Maintenance Therapy Following Adjuvant Oxaliplatin-based Chemotherapy in Patients with Stage III Colorectal Cancer after Radical Resection: Functional Roles of EGFR as a Potential Predictor

Ching-Wen Huang
,
Cheng-Jen Ma
,
Yi-Ting Chen
,
Hsiang-Lin Tsai
,
Yung-Sung Yeh
,
Wei-Chih Su
,
Tsung-Kun Chang
,
Wen-Hung Hsu
,
Fang-Jung Yu
,
Jaw-Yuan Wang
*
Version 1 : Received: 2 September 2019 / Approved: 4 September 2019 / Online: 4 September 2019 (00:53:56 CEST)

How to cite: Huang, C.; Ma, C.; Chen, Y.; Tsai, H.; Yeh, Y.; Su, W.; Chang, T.; Hsu, W.; Yu, F.; Wang, J. The Survival Impact of Fluoropyrimidine Metronomic Maintenance Therapy Following Adjuvant Oxaliplatin-based Chemotherapy in Patients with Stage III Colorectal Cancer after Radical Resection: Functional Roles of EGFR as a Potential Predictor. Preprints 2019, 2019090036. https://doi.org/10.20944/preprints201909.0036.v1 Huang, C.; Ma, C.; Chen, Y.; Tsai, H.; Yeh, Y.; Su, W.; Chang, T.; Hsu, W.; Yu, F.; Wang, J. The Survival Impact of Fluoropyrimidine Metronomic Maintenance Therapy Following Adjuvant Oxaliplatin-based Chemotherapy in Patients with Stage III Colorectal Cancer after Radical Resection: Functional Roles of EGFR as a Potential Predictor. Preprints 2019, 2019090036. https://doi.org/10.20944/preprints201909.0036.v1

Abstract

Background: This retrospective study evaluate the survival effects of metronomic maintenance therapy with fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. Methods: We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy on survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study and in vivo study through knockdout of EGFR gene, we analyzed the capacities of cell proliferation and migration. Results: Postoperative relapse and mortality were significantly more common in the FOLFOX group. Metronomic maintenance therapy was a significantly independent predictive factor of postoperative relapse and mortality, as well as a prognostic factor of disease-free survival and overall survival. We also demonstrated that EGFR-knockout Caco2 cells are more sensitive to the inhibition effect of fluoropyrimidine than the control those. Conclusions: The present study suggested EGFR expression as the prognostic factor in patients with stage III CRC receiving metronomic maintenance therapy. By analyzing EGFR expression and treatment strategies, we can identify the potential candidates with optimal survival benefit from metronomic maintenance therapy in patients with stage III CRC.

Keywords

fluoropyrimidine; metronomic maintenance therapy; oxaliplatin-based regimen; stage III colorectal cancer; epidermal growth factor receptor

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.